search
Back to results

Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Primary Purpose

Leukemia

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
cytarabine
idarubicin
Sponsored by
City of Hope Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia focused on measuring adult acute megakaryoblastic leukemia (M7), adult acute minimally differentiated myeloid leukemia (M0), adult acute monoblastic leukemia (M5a), adult acute monocytic leukemia (M5b), adult acute myeloblastic leukemia with maturation (M2), adult acute myeloblastic leukemia without maturation (M1), adult acute myelomonocytic leukemia (M4), adult erythroleukemia (M6a), adult pure erythroid leukemia (M6b), adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), secondary acute myeloid leukemia, untreated adult acute myeloid leukemia

Eligibility Criteria

16 Years - 60 Years (Child, Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

Inclusion criteria:

  • Newly diagnosed acute myeloid leukemia (AML)

    • Morphologic proof (bone marrow aspirate smears or touch prep of marrow biopsy) of disease
    • FAB M0, M1, M2, M4, M5a, M5b, M6a, M6b, and M7 disease
  • Previously untreated with radiotherapy or chemotherapy

    • Patients with treatment-related leukemia are eligible even if they have received prior chemotherapy and radiotherapy
  • Patients with prior myelodysplastic syndrome are eligible
  • Extramedullary leukemia allowed
  • AML with lymphoid markers allowed

Exclusion criteria:

  • Blastic transformation of chronic myelogenous leukemia
  • Biphenotypic leukemia
  • FAB M3 disease (acute promyelocytic leukemia)

PATIENT CHARACTERISTICS:

  • Life expectancy ≥ 6 weeks
  • Total bilirubin < 1.5 g/dL
  • AST and ALT < 5 times upper limit of normal (ULN)
  • Creatinine < 1.5 mg/dL OR creatinine clearance > 70 mL/min
  • Ejection fraction ≥ 50% by MUGA unless decreased ejection fraction is secondary to leukemia infiltration
  • HIV antibody-negative

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

  • See Disease Characteristics
  • Prior hydroxyurea or corticosteroids allowed
  • At least 48 hours since prior and no concurrent itraconazole or fluconazole

Exclusion criteria:

  • More than 300 mg/m² of prior daunorubicin or equivalent dose of anthracycline

Sites / Locations

  • Banner Good Samaritan Medical Center
  • City of Hope Comprehensive Cancer Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment (idarubicin, cytarabine)

Arm Description

Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with > 25% cellular biopsy or > 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.

Outcomes

Primary Outcome Measures

Complete Remission (CR)
The peripheral blood neutrophil count is >= 1.5 x 10^9 / L and platelets more than 100 x 10^9 / L. Leukemia blast cells are not present in the peripheral blood. The cellularity of the bone marrow is more than 20% with maturation of all cell lines. The bone marrow contains less than 5% blast cells, and Auer rods is not detectable.

Secondary Outcome Measures

Bone Marrow at Day 7 Post-Induction Chemotherapy
Bone marrow positive, negative cells at day 7 post-induction chemotherapy for leukemia (%)

Full Information

First Posted
September 10, 2007
Last Updated
December 12, 2016
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00528398
Brief Title
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Official Title
Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
September 1994 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving idarubicin together with high-dose cytarabine works in treating patients with acute myeloid leukemia.
Detailed Description
OBJECTIVES: Determine the complete remission rate (CR). Determine the proportion of patients who are bone marrow-positive at day 7 post-induction chemotherapy. Further evaluate the toxicity of this regimen. OUTLINE: Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with > 25% cellular biopsy or > 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia
Keywords
adult acute megakaryoblastic leukemia (M7), adult acute minimally differentiated myeloid leukemia (M0), adult acute monoblastic leukemia (M5a), adult acute monocytic leukemia (M5b), adult acute myeloblastic leukemia with maturation (M2), adult acute myeloblastic leukemia without maturation (M1), adult acute myelomonocytic leukemia (M4), adult erythroleukemia (M6a), adult pure erythroid leukemia (M6b), adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), secondary acute myeloid leukemia, untreated adult acute myeloid leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
111 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment (idarubicin, cytarabine)
Arm Type
Experimental
Arm Description
Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with > 25% cellular biopsy or > 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.
Intervention Type
Drug
Intervention Name(s)
cytarabine
Other Intervention Name(s)
Cytosine Arabinoside, Cytosar-U, Depocyt
Intervention Type
Drug
Intervention Name(s)
idarubicin
Other Intervention Name(s)
4-demethoxydaunorubicin, Idamycin, Zavedos
Primary Outcome Measure Information:
Title
Complete Remission (CR)
Description
The peripheral blood neutrophil count is >= 1.5 x 10^9 / L and platelets more than 100 x 10^9 / L. Leukemia blast cells are not present in the peripheral blood. The cellularity of the bone marrow is more than 20% with maturation of all cell lines. The bone marrow contains less than 5% blast cells, and Auer rods is not detectable.
Time Frame
7 days post completion of induction chemotherapy
Secondary Outcome Measure Information:
Title
Bone Marrow at Day 7 Post-Induction Chemotherapy
Description
Bone marrow positive, negative cells at day 7 post-induction chemotherapy for leukemia (%)
Time Frame
7 days post completion of induction chemotherapy

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Inclusion criteria: Newly diagnosed acute myeloid leukemia (AML) Morphologic proof (bone marrow aspirate smears or touch prep of marrow biopsy) of disease FAB M0, M1, M2, M4, M5a, M5b, M6a, M6b, and M7 disease Previously untreated with radiotherapy or chemotherapy Patients with treatment-related leukemia are eligible even if they have received prior chemotherapy and radiotherapy Patients with prior myelodysplastic syndrome are eligible Extramedullary leukemia allowed AML with lymphoid markers allowed Exclusion criteria: Blastic transformation of chronic myelogenous leukemia Biphenotypic leukemia FAB M3 disease (acute promyelocytic leukemia) PATIENT CHARACTERISTICS: Life expectancy ≥ 6 weeks Total bilirubin < 1.5 g/dL AST and ALT < 5 times upper limit of normal (ULN) Creatinine < 1.5 mg/dL OR creatinine clearance > 70 mL/min Ejection fraction ≥ 50% by MUGA unless decreased ejection fraction is secondary to leukemia infiltration HIV antibody-negative PRIOR CONCURRENT THERAPY: Inclusion criteria: See Disease Characteristics Prior hydroxyurea or corticosteroids allowed At least 48 hours since prior and no concurrent itraconazole or fluconazole Exclusion criteria: More than 300 mg/m² of prior daunorubicin or equivalent dose of anthracycline
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony S. Stein, MD
Organizational Affiliation
City of Hope Comprehensive Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Banner Good Samaritan Medical Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
City of Hope Comprehensive Cancer Center
City
Duarte
State/Province
California
ZIP/Postal Code
91010-3000
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

We'll reach out to this number within 24 hrs